CTBP1 strengthens the cisplatin resistance of gastric cancer cells by upregulating RAD51 expression

Wu,Yuluo; Zhao,Haiyang

doi:10.3892/ol.2021.13071

CTBP1 strengthens the cisplatin resistance of gastric cancer cells by upregulating RAD51 expression

Authors:
- Yuluo Wu
- Haiyang Zhao
View Affiliations

Affiliations: Department of Oncology, Guangdong Medical University Affiliated Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong 524000, P.R. China, Department of Oncology, Beijing Zhongguancun Hospital, Beijing 100190, P.R. China
Published online on: September 27, 2021 https://doi.org/10.3892/ol.2021.13071
Article Number: 810
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is a key factor affecting the treatment of gastric cancer. The resistance of gastric cancer cells to anticancer drugs, such as cisplatin (DDP), remains a major challenge to patient recovery. The present study aimed to investigate the roles of C‑terminal‑binding protein 1 (CTBP1) in the DDP resistance of gastric cancer cells and to determine its regulatory effect on DNA repair protein RAD51 homolog 1 (RAD51). The DDP‑resistant human gastric cancer AGS and HGC cell lines, AGS/DDP and HGC‑27/DDP, respectively, were established and CTBP1 expression was detected by western blotting. In addition, Cell Counting Kit‑8, colony formation and flow cytometry assays were performed to detect the proliferation and apoptosis of these two cell lines following CTBP1 knockdown. The expression levels of apoptosis‑related proteins were detected by western blotting. In addition, RAD51 was overexpressed in CTBP1 knockdown cells, and proliferation and apoptosis were subsequently determined using the aforementioned methods. The results demonstrated that CTBP1 expression was notably increased in DDP‑resistant gastric cancer cells. Furthermore, CTBP1 knockdown suppressed the proliferation and induced the apoptosis of AGS/DDP and HGC‑27/DDP cells. Notably, CTBP1 promoted RAD51 expression in DDP‑resistant gastric cancer cells. Overexpression of RAD51 in CTBP1 knockdown AGS/DDP and HGC‑27/DDP cells rescued the proliferation and alleviated the apoptosis of these cells. Taken together, the results of the present study suggested that CTBP1 may enhance the DDP resistance of gastric cancer cells by activating RAD51 expression, thus providing a potential novel therapy (CTBP1 knockdown) for the clinical treatment of patients with gastric cancer.

View Figures

View References

1	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Clevers H: The cancer stem cell: Premises, promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
4	Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
5	Huang C, Chen R, Zheng F, Tang Y, Wang X, Chen Z and Lai X: Inhibitory role of ATF3 in gastric cancer progression through regulating cell EMT and stemness. Cancer Cell Int. 21:1272021. View Article : Google Scholar : PubMed/NCBI
6	Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, et al: Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial. Lancet Oncol. 19:616–628. 2018. View Article : Google Scholar : PubMed/NCBI
7	Koizumi W, Tanabe S, Azuma M, Ishido K, Nishimura K, Sasaki T, Nakatani K, Higuchi K, Nakayama N and Katada C: Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 126:162–170. 2010. View Article : Google Scholar : PubMed/NCBI
8	Liu Y, Bian T, Feng J, Qian L, Li X, Zhang Q, Zhang J, Jiang D, Liu J and Shi J: CtBP1 interacts with SOX2 to promote the growth, migration and invasion of lung adenocarcinoma. Oncol Rep. 42:67–78. 2019.PubMed/NCBI
9	Wang Y, Dai C, Zhou C, Li W, Qian Y, Wen J, Wang Y, Han B, Ma J, Xu J, et al: Benzotriazole enhances cell invasive potency in endometrial carcinoma through CTBP1-mediated epithelial-mesenchymal transition. Cell Physiol Biochem. 44:2357–2367. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhao C, Shen Y, Tao X, Xu J, Lu J, Liu C, Xu Z, Tang Q, Tao T and Zhang X: Silencing of CtBP1 suppresses the migration in human glioma cells. J Mol Histol. 47:297–304. 2016. View Article : Google Scholar : PubMed/NCBI
11	Moiola CP, De Luca P, Zalazar F, Cotignola J, Rodríguez-Seguí SA, Gardner K, Meiss R, Vallecorsa P, Pignataro O, Mazza O, et al: Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice. Clin Cancer Res. 20:4086–4095. 2014. View Article : Google Scholar : PubMed/NCBI
12	Porretti J, Dalton GN, Massillo C, Scalise GD, Farré PL, Elble R, Gerez EN, Accialini P, Cabanillas AM, Gardner K, et al: CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease. Int J Cancer. 143:897–906. 2018. View Article : Google Scholar : PubMed/NCBI
13	Dcona MM, Morris BL, Ellis KC and Grossman SR: CtBP-an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors. Cancer Biol Ther. 18:379–391. 2017. View Article : Google Scholar : PubMed/NCBI
14	Han Y, Bi Y, Bi H, Diao C, Zhang G, Cheng K and Yang Z: miR-137 suppresses the invasion and procedure of EMT of human breast cancer cell line MCF-7 through targeting CtBP1. Hum Cell. 29:30–36. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhou J, Su M, Zhang H, Wang J and Chen Y: miR-539-3P inhibits proliferation and invasion of gastric cancer cells by targeting CTBP1. Int J Clin Exp Pathol. 12:1618–1625. 2019.PubMed/NCBI
16	Wang C, Wang M, Xing B, Chi Z, Wang H, Lie C and Dong H: C-terminal of E1A binding protein 1 enhances the migration of gastric epithelial cells and has a clinicopathologic significance in human gastric carcinoma. Onco Targets Ther. 12:5189–5200. 2019. View Article : Google Scholar : PubMed/NCBI
17	Deng Y, Guo W, Xu N, Li F and Li J: CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells. Mol Carcinog. 59:512–519. 2020. View Article : Google Scholar : PubMed/NCBI
18	Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR and Bishop DK: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 275:23899–23903. 2000. View Article : Google Scholar : PubMed/NCBI
19	Feng Y, Wang D, Xiong L, Zhen G and Tan J: Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer. Cancer Cell Int. 21:2492021. View Article : Google Scholar : PubMed/NCBI
20	Mattiello L, Soliman Abdel Rehim S, Musella M, Sistigu A, Guarracino A, Vitale S, Corradi F, Galassi C, Sperati F, Manic G, et al: The targeting of MRE11 or RAD51 sensitizes colorectal cancer stem cells to CHK1 inhibition. Cancers (Basel). 13:19572021. View Article : Google Scholar : PubMed/NCBI
21	Malka MM, Eberle J, Niedermayer K, Zlotos DP and Wiesmuller L: Dual PARP and RAD51 inhibitory drug conjugates show synergistic and selective effects on breast cancer cells. Biomolecules. 11:9812021. View Article : Google Scholar : PubMed/NCBI
22	Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, et al: STAT5A/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair. Clin Cancer Res. 24:1917–1931. 2018. View Article : Google Scholar : PubMed/NCBI
23	Yang X, Zhang Q and Guan B: Circ_0110805 knockdown enhances cisplatin sensitivity and inhibits gastric cancer progression by miR-299-3p/ENDOPDI axis. OncoTargets Ther. 13:11445–11457. 2020. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
26	Sun TT, He J, Liang Q, Ren LL, Yan TT, Yu TC, Tang JY, Bao YJ, Hu Y, Lin Y, et al: lncRNA GClnc1 promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. Cancer Discov. 6:784–801. 2016. View Article : Google Scholar : PubMed/NCBI
27	Sun Y, Ma J, Lin J, Sun D, Song P, Shi L, Li H, Wang R, Wang Z and Liu S: Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis. Anti-Cancer Drugs. May 19–2021.(Epub ahead of print). doi: 10.1097/CAD.0000000000001087. View Article : Google Scholar
28	Zhang S, Feng R, Yuan F, Luo Q, Chen X, Li N and Yang S: The therapeutic effects of dihydroartemisinin on cisplatin-resistant gastric cancer cells. Curr Pharm Biotechnol. Feb 16–2021.(Epub ahead of print). doi: 10.2174/1389201022666210217114825. View Article : Google Scholar
29	Zhuo W, Liu Y, Li S, Guo D, Sun Q, Jin J, Rao X, Li M, Sun M, Jiang M, et al: Long noncoding RNA GMAN, Up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of ephrin A1 by competitively binding GMAN-AS. Gastroenterology. 156:676–691.e11. 2019. View Article : Google Scholar : PubMed/NCBI
30	Chinnadurai G: The transcriptional corepressor CtBP: A foe of multiple tumor suppressors. Cancer Res. 69:731–734. 2009. View Article : Google Scholar : PubMed/NCBI
31	Chen X, Zhang Q, Dang X, Song T, Wang Y, Yu Z, Zhang S, Fan J, Cong F, Zhang W and Duan N: Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells. J Cancer. 12:482–497. 2021. View Article : Google Scholar : PubMed/NCBI
32	He Y, He Z, Lin J, Chen C, Chen Y and Liu S: CtBP1/2 differentially regulate genomic stability and DNA repair pathway in high-grade serous ovarian cancer cell. Oncogenesis. 10:492021. View Article : Google Scholar : PubMed/NCBI
33	Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, et al: RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer. Clin Cancer Res. 23:514–522. 2017. View Article : Google Scholar : PubMed/NCBI
34	He WL, Li YH, Hou WJ, Ke ZF, Chen XL, Lu LY, Cai SR, Song W, Zhang CH and He YL: RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer. World J Gastroenterol. 20:10094–10107. 2014. View Article : Google Scholar : PubMed/NCBI